Iron-deficiency Clinical Trial
Official title:
The Effects of Iron Aid IPS on Performance, Fatigue and Iron Levels During 12 Weeks of Supplementation and Aerobic Training
Participants are required to undergo a screening and qualification before beginning the study. Once qualified, baseline testing is completed in the laboratory. This testing includes: body composition measurements, a blood draw, questionnaires, a VO2 max test, and a time to exhaustion trial. This testing is repeated during week 4 and week 12. At week 8, subjects complete a blood draw and questionnaires only. During the 12 week period, participants will follow an endurance exercise program in which they will train 4 days per week. This is a double-blind study in which participants are randomized into either the placebo or supplement group. They are instructed to ingest the supplement once a day at breakfast. Diet logs are also monitored throughout the duration of the study with the restriction of no red meat.
Subjects expressing interest in participating in this study, were interviewed in person to
determine whether they appeared to qualify to participate in the study. If they met
eligibility criteria, they were invited to attend an entry/familiarization session. During
this session, they completed personal and medical histories which were reviewed to determine
whether they met eligibility criteria. Once meeting entry criteria, they were familiarized to
the study protocol via a verbal and written explanation outlining the study design. Subjects
then read and signed the Informed Consent Statements after the study details were explained.
Subjects then perform the exercise protocol in which they must have completed in order to
qualify for the study.
Subjects were asked to perform a VO2 Max test using the Bruce protocol. Following the VO2 Max
test, subjects were given a rest period of 20 minutes before starting the Time to Exhaustion
(TTE) trial run. This session familiarized subjects with the exercise protocol preparing them
for the qualification testing session. Subjects then returned to the lab in a 12 hour fasted
state and completed a VO2max test. If a 42 ml/kg/min or above was achieved subjects were then
allowed to complete the 20 minute TTE test. After completion of the TTE, a blood draw was
done to access the subject's iron levels. Once results for iron levels returned at a 90 or
below subjects were given an appointment time to perform baseline assessments and testing
sessions.
Baseline testing (Week 0), Week 8 and Week 12 took place on the 8th or 9th day after the
subject's menstrual cycle. Subjects returned to the lab in a 12 hour fasted state, with no
strenuous workouts done 48 hours prior to testing. Subjects had their height and weight
measured, filled out questionnaires, completed a DEXA scan and InBody to establish current
body composition, afterwards having their heart rate and blood pressure assessed. At this
point subjects were instructed to lay on a table for their blood draw. Once the blood draw
was done, subjects completed a VO2 Max test using the Bruce protocol. Following the VO2 Max
testing, subjects filled out 2 questionnaires and were given a rest period of 20 minutes
before starting the Time to Exhaustion (TTE) trial run. During the rest period subjects were
given a snack to ingest (banana or apple) and consumed the same snack at each testing
session. Approximately 12 minutes prior to the TTE subjects filled out a questionnaire.
During the TTE run subjects were able to control and see the speed at which they ran but were
blinded to the time passed along with the distance completed. After the 20 minutes, the
treadmill stopped, distance, heart rate and blood pressure were measured. Afterwards,
subjects filled out post exercise questionnaires. At week 0, after all exercise testing was
completed, subjects were assigned to a group (either placebo or active) and instructed to
ingest 1 capsule per day. A workout log was also provided to each subject, who would return
to the lab every Friday with their workout log to access exercise compliance.
At week 4, subjects returned to the lab on the 8th or 9th day after their menstrual cycle to
have a blood draw completed to access blood marker variables in addition to questionnaires.
Diet logs were keep throughout the duration of the study and were monitored by lab staff.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04949165 -
Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
|
N/A | |
Terminated |
NCT03218384 -
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
|
Phase 2 | |
Active, not recruiting |
NCT03516734 -
Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh
|
N/A | |
Completed |
NCT03572010 -
Stable Iron Isotope Method in HIV+ and HIV- Children
|
N/A | |
Active, not recruiting |
NCT03703726 -
Iron Absorption From Fortified Extruded Rice Using Different Extruding Temperatures.
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Not yet recruiting |
NCT05395468 -
Diagnosis of Iron Deficiency by Artificial Intelligence Analysis of Eye Photography.
|
||
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Not yet recruiting |
NCT03353662 -
Sub Regional Micronutrient Survey in Ethiopia
|
||
Completed |
NCT03819530 -
Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study
|
N/A | |
Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
Completed |
NCT03957057 -
Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia
|
Phase 3 | |
Completed |
NCT03642223 -
Central and Peripheral Adiposity and Iron Absorption
|
N/A | |
Not yet recruiting |
NCT05407987 -
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
|
Phase 3 | |
Withdrawn |
NCT03873584 -
Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
|
||
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Completed |
NCT04359368 -
Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions
|
||
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Enrolling by invitation |
NCT05750940 -
Oxidative Skeletal Muscle Metabolism in Chronic Heart Failure Patients With and Without Iron Deficiency
|
||
Recruiting |
NCT05126901 -
Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
|
Phase 3 |